Stockwinners Market Radar for October 28, 2023 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

17:35 EDT Airbnb exec sells $3.12M in common stock - In a regulatory filing, Airbnb disclosed that its Chief Strategy Officer Nathan Blecharczyk sold 26.1K shares of common stock on October 25th in a total transaction size of $3.12M.

17:15 EDT FOXO Technologies announces reverse stock split - FOXO Technologies announced that its Board of Directors has approved a 1-for-10 reverse stock split of the Company's Class A common stock, par value $0.0001. The reverse stock split will become effective at 4:01pm ET on November 6, 2023. The Common Stock is expected to begin trading on a split-adjusted basis on the NYSE American under the same symbol "FOXO" when the market opens on November 7, 2023, with the new CUSIP number 351471305. The reverse stock split was approved by the Company's stockholders at the Company's 2023 Annual Meeting, held on May 26, 2023, at a ratio ranging from 1-for-10 to 1-for-100. As a result of the reverse stock split, every 10 shares of Common Stock issued and outstanding will be automatically combined into one share of Common Stock, with no change in the $0.0001 par value per share. Holders of fractional shares will be entitled to receive the number of shares rounded up to the next whole number.

17:07 EDT Korn Ferry to cut about 8% of workforce, sees pretax charge of $55M-$65M - According to a regulatory filing, in light of the challenging macroeconomic business environment arising from persistent inflationary pressures, rising interest rates and global economic and geopolitical uncertainty, on October 23, 2023, Korn Ferry initiated a plan intended to align its workforce with its current business realities through position eliminations, which will affect approximately eight percent of the company's employees. The Plan is expected to be substantially completed by the end of the third quarter of fiscal 2024. The Plan is expected to reduce the company's annualized cost base by approximately $110M to $120M and is expected to result in an estimated pre-tax charge of approximately $55M to $65M, consisting of severance and related employee benefit payments. These charges are expected to include approximately $40M to $45M of cash expenditures, the majority of which will be paid during the remainder of fiscal 2024.

16:47 EDT LumiraDx receives Nasdaq delisting determination, plans to appeal - On October 24, 2023, LumiraDx received a notice from the Listing Qualifications Department of The Nasdaq Stock Market stating that on April 21, 2023, the Staff had notified the company that the bid price of its listed securities had closed at less than $1.00 per share over the previous 30 consecutive business days, and, as a result, did not comply with Listing Rule 5450(a)(1). Therefore, in accordance with Listing Rule 5810(c)(3)(A), the company was provided 180 calendar days, or until October 18, 2023, to regain compliance with the Minimum Bid Price Requirement. The Notice states that because the company has not regained compliance with the Minimum Bid Price Requirement, its securities are now subject to delisting from The Nasdaq Global Market. The Notice indicates that unless the company appeals the delisting determination, which it intends to do, trading of the company's securities will be suspended at the opening of business on November 2, 2023, and a Form 25-NSE will be filed with the U.S. SEC, which will remove the company's securities from listing and registration on Nasdaq. The Notice stated that the company may appeal Staff's determination to a Hearings Panel pursuant to the procedures set forth in the Nasdaq Listing Rule 5800 Series. A hearing request will stay the suspension of the company's securities and the filing of the Form 25-NSE pending the Panel's decision. The company intends to request a hearing to appeal the delisting determination. The company is working on a plan to present to the Panel in an effort to regain compliance with the Listing Rules.

16:40 EDT Intuitive Machines sets January 2024 for IM-1 lunar mission - Intuitive Machines announced that in coordination with SpaceX, liftoff of the IM-1 lunar mission is now targeted for a multi-day launch window which opens January 12, 2024. "As previously announced, Intuitive Machines completed its lunar lander in September, and the entire company is looking forward to our upcoming launch," said Steve Altemus, Co-Founder, President, and Chief Executive Officer. "There are inherent challenges of lunar missions; schedule changes and mission adjustments are a natural consequence of pioneering lunar exploration. Receiving a launch window and the required approvals to fly is a remarkable achievement, and the schedule adjustment is a small price to pay for making history."

16:28 EDT Tupperware Brands: PwC declines to stand for re-appointment as auditor - On October 24, PricewaterhouseCoopers LLP informed Tupperware Brands that PwC is declining to stand for re-appointment as the company's registered public accounting firm for the integrated audit of the fiscal year ending December 30, 2023. There is no dispute between the company and PwC. PwC's reports on the company's financial statements for the fiscal years ended December 31, 2022 and December 25, 2021 contained no adverse opinion or disclaimer of opinion and were not qualified or modified as to uncertainty, audit scope or accounting principles, except that the report for the fiscal year ended December 31, 2022 included an explanatory paragraph indicating that there was substantial doubt about the company's ability to continue as a going concern. The company will disclose its engagement of a new independent registered public accounting firm once the evaluation process has been completed and as required by, and in accordance with, the SEC's rules and regulations.

16:17 EDT Leidos raises quarterly dividend to 38c from 36c per share - The cash dividend is payable on December 29 to stockholders of record as of the close of business on December 15.

16:06 EDT SaverOne 2014 receives noncompliance notice from Nasdaq - SaverOne 2014 announced that the company received a written notice from Nasdaq indicating that the company was not in compliance with Nasdaq Listing Rule 5550, as the company's closing bid price for its American Depositary Shares was below $1.00 per share for the last 30 consecutive business days.

15:09 EDT Coherus Biosciences, Junshi Biosciences announce FDA approval of LOQTORZI - Coherus BioSciences and Shanghai Junshi Biosciences announced that the U.S. FDA approved LOQTORZI in combination with cisplatin and gemcitabine for the first-line treatment of adults with metastatic or recurrent locally advanced NPC, and as monotherapy for the treatment of adults with recurrent, unresectable, or metastatic NPC with disease progression on or after platinum-containing chemotherapy. The approval was based on results of the JUPITER-02 Phase 3 study and the POLARIS-02 Phase 2 study and is irrespective of a patient's PD-L1 status. LOQTORZI is a next-generation, programmed death receptor-1 monoclonal antibody that blocks PD-1 ligands PD-L1 and PD-L2 with high potency at a unique site on the PD-1 receptor, enabling the immune system to activate and kill the tumor. LOQTORZI is expected to be available in the United States in Q1 2024.

14:31 EDT Twin Ridge Capital Acquisition Corp trading resumes

14:09 EDT Scilex files emergency motion with bankruptcy court for production of records - Scilex (SCLX) announced that it filed an emergency motion for entry of an order compelling the production of books and records from certain brokers, dealers, banks and other nominees pursuant to Rule 2004 of the federal rules of bankruptcy procedure in the U.S. Bankruptcy Court for the Southern District of Texas. "As previously noted, Scilex believes that, with no objections from the participating Short Sellers and with widespread support and assistance from such Short Sellers' brokers and/or agents, there should be no further excuses for continuing to hold the short positions in Scilex. The Short Seller Proposal provided those Short Sellers with the opportunity to cover their short positions and avoid any continuing fees, interest, and other expenses associated with any short positions, as well as an opportunity to accept the terms provided in Sorrento's ongoing Chapter 11 proceedings in order to obtain a release from Scilex for any claims and causes of action related to any potential naked short selling or other similar market manipulative behavior. The Short Seller Proposal ended on October 27," the company stated. On October 3, Scilex provided a proposal to parties with short positions in shares of Scilex common stock that were part of the previously announced dividend of Scilex common stock then-held by Sorrento Therapeutics (SRNEQ) who had not yet closed or covered their respective short positions in the Scilex Dividend Stock, the company noted.

13:02 EDT Baker Hughes reports U.S. rig count up 1 to 625 rigs - Baker Hughes reports the U.S. rig count is up 1 from last week to 625, with oil rigs up 2 to 504, gas rigs down 1 to 117 and miscellaneous rigs unchanged at 4. The U.S. rig count is down 143 rigs from last year's count of 768, with oil rigs down 106, gas rigs down 39 and miscellaneous up 2. The U.S. offshore rig count is unchanged at 24, up 10 year-over-year.

12:02 EDT NOV Inc. sees Q4 EBITDA in '$300M range' - NOV Inc. CFO Jose Bayardo said during the company's Q3 earnings call, according to a transcript: "For consolidated company results, we believe building momentum in numerous of markets, including rising exploration activity, along with continued growth in the Middle East, will more than offset soft North American land activity, enabling EBITDA to reach the $300M range with much improved cash flow in the fourth quarter."

12:00 EDT Kinsale Capital falls -16.2% - Kinsale Capital is down -16.2%, or -$69.10 to $357.12.

12:00 EDT Barnes Group falls -26.6% - Barnes Group is down -26.6%, or -$7.97 to $22.01.

12:00 EDT Adtalem Global Education rises 13.9% - Adtalem Global Education is up 13.9%, or $6.00 to $49.15.

11:31 EDT Chevron sees share of TCO dividend down by $2.5B for 2024, 2025 - Says Venezuela output up to 130,000 barrels per day from 60,000 barrels earlier this year. Says Grand Rapids steaming to start by the end of the year. Says produced water becoming in issue in Permian Basin.

11:04 EDT Axalta Coating named exclusive supplier for BMW's private paint label - Axalta Coating Systems (AXTA) has been named exclusive supplier for BMW Group's (BMWYY) private paint label, ColorSystem, in currently 15 Europeans countries plus South Africa. The agreement includes BMW Group's network of 730 dealerships and collision repair partners. As part of the agreement, Axalta will also provide its latest, innovative Fast Cure Low Energy technology paint system. The agreement runs through December 2028 and adds to existing supplier agreements with BMW Group.

10:53 EDT American Acquisition Opportunity Inc trading resumes

10:33 EDT Principal sees two large institutional outflows to impact net cash flow by $5B - Daniel Houston, Chairman, President and CEO of Principal Financial, stated during the company's earnings call, according to a transcript: "We have several real estate opportunities boosting our optimism for the coming quarters. We expect additional funding in the fourth quarter in our new data center fund and our China real estate joint venture as discussed last quarter. We have a strong pipeline of committed yet unfunded real estate mandates currently over $6B that we will put to work opportunistically. Looking at asset management in total, we are aware of two large institutional outflows of similar size that will impact net cash flow by approximately $5B in total. One client is planning to take the funds in-house while the other is moving to a passive option. We expect one of the outflows to occur in the fourth quarter and the other early in the first quarter of 2024." Principal Financial shares are down about 1% to $67.83 in morning trading.

10:25 EDT Data Knights Acquisition Corp trading halted, volatility trading pause

10:19 EDT Tyler Technologies signs contract with U.S. National Guard Bureau - Tyler Technologies has signed a contract with the U.S. National Guard Bureau, and specifically the NGB-DEI Complaints Management and Adjudication Branch, for Tyler's Workforce Case Management application suite. Tyler will provide a web-based case management, complaint tracking, and program management and reporting application for military equal opportunity and civilian equal employment opportunity professionals. Tyler's applications will provide field and program oversight while ensuring transparency to complainants, alleged offenders, commanders, and senior leaders, as well as accountability for substantiated claims and notices of proposed resolutions. The Workforce Case Management suite will manage informal and formal harassment and discrimination complaint activities through the entire workflow.

10:13 EDT Newell says hasn't seen 'a big opportunity to break up the portfolio' to date - Commenting on the company's previously announced strategic review plans during the company's earnings call, executives at Newell Brands stated in part, according to a transcript: "So when we announced the strategy in June, we had -- at that point in time, we had 80 brands that we were selling across the company... And so we feel like we've got now a portfolio from the divestitures that have been completed over the last 5 years that fits together and where there is scale that can be leveraged... So we continue to look at is the portfolio the right thing and is there value to be unlocked but to date, we have not seen that there's a big opportunity to break up the portfolio and drive value because we believe the dissynergies and the tax impact would overwhelm any value we would get from a major divestiture. That being said, we also very clearly said that we don't think 80 brands is the right answer. And so as part of the strategy, we said we're going to prioritize the top 25 brands because they represent 90% of the sales and profit of the company. We are moving at pace since we announced that strategy in June. And as I mentioned in my prepared remarks, we expect to be down from 80 brands down to 60 by the end of this year. So that's already a meaningful reduction in the number of brands in the portfolio, and we think we'll continue to reduce the number of brands over time."

10:11 EDT WestRock increases quarterly dividend to 30.25c per share - WestRock Company reported that its board of directors declared a quarterly dividend of 30.25c per share on its common stock, an increase of 27.50c per share from its previous quarterly dividend which represents an annualized increase of 11c per share, or 10%. The quarterly dividend of 30.25c per share will be paid to stockholders of record as of the close of business on November 13, 2023, and will be paid on November 21, 2023.

10:06 EDT Forbion European Acquisition Corp trading resumes

10:00 EDT Kinsale Capital falls -13.7% - Kinsale Capital is down -13.7%, or -$58.48 to $367.74.

10:00 EDT Customers Bancorp rises 12.6% - Customers Bancorp is up 12.6%, or $4.24 to $37.99.

10:00 EDT Deckers Outdoor rises 15.2% - Deckers Outdoor is up 15.2%, or $73.72 to $558.30.

09:55 EDT Realpha Tech Corp. trading resumes

09:47 EDT NatWest Group falls -11.4% - NatWest Group is down -11.4%, or -58c to $4.50.

09:47 EDT Juniper rises 13.2% - Juniper is up 13.2%, or $3.32 to $28.40.

09:47 EDT Deckers Outdoor rises 14.0% - Deckers Outdoor is up 14.0%, or $67.78 to $552.36.

09:42 EDT Newell Brands trading resumes

09:36 EDT U-Haul enters exclusive partnerhip with Moved - U-Haul announced an exclusive partnership with resident technology company Moved. The agreement includes exclusive rights for both U-Haul and Moved's business-to-business-to-consume software, which streamlines the onboarding and offboarding process for tenants of multifamily communities.

09:30 EDT Acumen presents Phase 1 updates on ACU193 in early AD - Acumen Pharmaceuticals presented further analyses of the Phase 1 INTERCEPT-AD trial evaluating ACU193, the first clinical-stage AbetaO-targeting antibody, at the 16th Annual Clinical Trials on Alzheimer's Disease conference in Boston and online. The additional analyses reveal robust target engagement data modeling informing dose selection for Acumen's upcoming Phase 2/3 trial, as well as further details and characteristics around the observed plaque reduction and relatively low overall levels of ARIA-E during a late breaking symposium. Acumen additionally presented new target engagement and pharmacokinetic analyses from clinical trial recruitment in four posters at the conference. Acumen plans to progress to a Phase 2/3 clinical study, with the Phase 2 portion planned to begin in the first half of 2024.: Positive topline results from the Phase 1 INTERCEPT-AD, announced in July 2023, demonstrated that ACU193 was well-tolerated with a compelling overall safety profile, meeting the primary objective of this Phase 1 study in both single- and multiple-dose regimens in 62 participants with early AD. Results also demonstrated dose related plaque reduction, low overall ARIA-E and PK results supporting dosing of ACU193 every four weeks, ultimately confirming proof-of-mechanism for the first clinical-stage monoclonal antibody designed to selectively bind AbetaOs while potentially offering improved safety and clinical benefit over existing amyloid-directed therapies. Further analyses and data modeling of the robust Phase 1 dataset, presented at CTAD, shed deeper insights into the broad therapeutic potential of ACU193 and the clinical validity of targeting AbetaOs, while helping to inform the subsequent Phase 2/3 study that will assess clinical efficacy. In a late-breaking symposium, titled "INTERCEPT-AD phase 1 insights and findings from the investigation of ACU193, a monoclonal antibody targeting soluble Abeta oligomers," detailed results were discussed during the following presentations: Determination of Target Engagement at Various Doses of ACU193 in INTERCEPT-AD: ACU193 demonstrated direct target engagement of toxic AbetaOs in a dose-proportional manner, using a novel assay to measure cerebral spinal fluid concentrations of ACU193 bound to AbetaOs, which approached maximal target engagement with higher doses of ACU193. Further analysis of this novel endpoint, based on robust pharmacokinetic/pharmacodynamic data modeling conducted in collaboration with Certara, demonstrated the pharmacokinetics of ACU193 in CSF and its correlation with dose and dose regimen and serum PK. Modeling the target engagement Emax curve offered the opportunity to select doses of 35 and 50 mg/kg with substantial target engagement of AbetaOs for the Phase 2/3 study. Amyloid plaque reduction results from the Phase 1 trial were also considered in the selection of 35 and 50 mg/kg doses, which will be evaluated versus placebo in the Phase 2/3 study. Reduction in Amyloid Plaque Load at Higher Doses of ACU193 in INTERCEPT-AD: In INTERCEPT-AD, dose-related, statistically significant amyloid plaque reduction that was comparable to approved and in-review therapies at similar time points, was observed in higher dose cohorts. This finding demonstrates ACU193's activity in the brain and is a positive development given the relationship between robust plaque reduction and slowing clinical decline established by other Abeta-targeting antibodies. The amyloid positron emission tomography data for inclusion in the study were assessed using a hybrid approach to evaluating amyloid positivity in PET scans based on SUVr and, in some cases, visual reads, which may be useful in detecting amyloid positivity below the SUVr threshold. These visual reads may be of particular importance for patients with early AD. The presentation also explored potential mechanistic explanations for the unexpected plaque reduction effect of ACU193 with limited ARIA-E, given its selectivity for AbetaOs and minimal binding of other Abeta species. A Phase 2/3 study is planned to assess primarily the clinical efficacy of ACU193 and also to more fully understand its effect on plaques. Characteristics of Participants in INTERCEPT-AD Who Did or Did Not Develop ARIA with ACU193: As previously reported, the INTERCEPT-AD study demonstrated overall low incidence of ARIA-E, with five cases of ARIA-E in the 48 participants treated with ACU193. In further subgroup data, as presented by Dr. Stephen Salloway, M.D., M.S., Alpert Medical School of Brown University, four of the five cases of ARIA-E occurred in APOE4 heterozygotes and none in APOE4 homozygotes. The presentation also detailed characteristics among participants who did and did not experience amyloid plaque reduction, helping to shed light on possible explanations for the variability in the reduction of plaque load seen in different participants.

09:18 EDT Yoshitsu enters strategic cooperation with Tasly Holding Group - Yoshitsu announced that on October 18, 2023, the Company entered into a strategic cooperation agreement with Tasly Holding Group to cooperate with the investment, research and development, and sales of health products globally. Yoshitsu expects this collaboration with Tasly to help solidify and grow Yoshitsu's presence in the health product sector. Yoshitsu and Tasly also plan to assist each other with the registration and approval procedures necessary for health products to be sold in Japan, mainland China, Hong Kong, Macau, and other overseas markets. Yoshitsu and Tasly aim to utilize their respective sales networks and logistics distribution systems to help each other improve their respective supply chain systems and distribution channels in international markets.

09:15 EDT AgriFORCE Growing Systems regains compliance with Nasdaq listing requirements - AgriFORCE Growing Systems announced that the Company received notice from Nasdaq on October 26, 2023, indicating that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2).

09:02 EDT Paramount and Sinclair Broadcast sign agreement for 21 CBS network affiliations - Paramount (PARA) and Sinclair (SBGI) announced comprehensive, multi-year distribution agreements across all 21 CBS network affiliations for Sinclair stations, including six top-50 market affiliates, KUTV in Salt Lake City, UT, KEYE in Austin, TX, WKRC in Cincinnati, OH, WPEC in West Palm Beach, FL, WWMT in Grand Rapids, MI and WHP in Harrisburg, PA. Additionally, Paramount reached an agreement to renew the affiliation of WTVH in Syracuse, NY and WGFL in Gainesville, FL, stations to which Sinclair provides services. The 23 markets combined reach 8% of the U.S. audience serving over 10 million television households.

08:41 EDT Thumzup welcomes The Gym Venice to cash rewards platform - Thumzup Media Corporation welcomes The Gym Venice, located at 12257 Venice Blvd., Los Angeles, California, to its AdTech platform, offering cash rewards for social media endorsements of advertising businesses.

08:34 EDT Kingsway Financial acquires Digital Diagnostics Imaging for $11M - Kingsway Financial Services announced the acquisition of Digital Diagnostics Imaging, a provider of fully managed outsourced cardiac monitoring telemetry services for $11M in an all-cash transaction funded with $5.4M in cash on hand and $5.6M in debt financing. Digital Diagnostics Imaging provides fully managed outsourced cardiac monitoring telemetry services to long-term acute care and inpatient rehabilitation hospitals throughout the U.S. The business enables remote access to client hospital telemetry systems from an outsourced monitoring station ensuring that a patient's ECG is continuously under watch. All technicians are certified by nationally-recognized organizations. DDI has been operating for over 10 years and currently has a presence in 42 states. The transaction was structured as a purchase of all of the issued and outstanding shares of capital stock of DDI. Financing was provided by Signature Bank. Holland & Knight LLP served as legal counsel to Kingsway, and Sichenzia Ross Ference Carmel LLP served as legal counsel to the sellers in connection with the transaction.

08:24 EDT American Battery reports results of lithium-bearing Tonopah Flats drilling - American Battery announced positive drill results from its third exploration drill program at its Tonopah Flats Lithium Project in Big Smoky Valley, Nevada. The infill and step-out drill program consisted of 8 holes totaling approximately 6,700 feet of sampling and achieved the target core drilling depth of over 1,400 feet. Highlights from this third drill program include: the vast majority of samples analyzed, up to 99% per hole, demonstrated lithium concentrations above the reference cutoff concentration of 300 ppmw. These intervals of high concentrations were observed in all 6 holes and throughout a large percentage of the total sampled depths, and with significantly higher peak concentrations observed in many sample holes. Anomalous lithium concentrations were measured at very shallow depths, less than 20 feet below the surface in many cases, indicating that low-cost and low-strip ratio techniques can likely be applied to access these near-surface lithium-bearing sedimentary materials. In several drill holes the significant mineralization of lithium is still present at these depths, indicating that the anomalous lithium presence could extend even beyond the sampled depths. ABTC controls 100% of the mining lode claims comprising the Tonopah Flats claims and the rights to all locatable minerals without any royalties. The Maiden Resource Report in February concluded that this deposit is one of the largest known lithium resources in the U.S., containing approximately 15.8 million tons of economically-accessible lithium on a carbonate equivalent basis. ABTC will further evolve this project with plans to construct a commercial-scale lithium hydroxide refinery utilizing this system design.

08:11 EDT Telus Pollinator Fund invests in three new clean tech startups - TELUS Pollinator Fund for Good is participating in three new funding rounds of $20M, $6.5M, and $4M respectively with equity investments in clean technology startups, Climate Robotics, erthos and Plentify. "As a global leader in sustainability, TELUS' readiness and capability to swiftly deploy capital to help scale clean tech innovations will contribute to promote adoption of zero-emission solutions," said Blair Miller, Managing Partner, TELUS Pollinator Fund. "That's why the Pollinator Fund is investing in Climate Robotics, erthos and Plentify: to play an active role in sequestering CO2, solving the plastic crisis and addressing the global pressure on electricity grids, thereby contributing to climate resilience and the circular economy."

08:10 EDT Oxford Lane estimates Q3 NAV per share $4.74-$4.84 - The Company's preliminary estimate of its net asset value per share for the quarter ended September 30, 2023 is $4.74 to $4.84, which is consistent with the range previously announced by the Company in its unaudited estimate range of NAV per share as of August 31, 2023.

08:09 EDT GDEV Inc. announces global release of Island Hoppers - GDEV announces the global release of its game Island Hoppers following the successful completion of its soft launch. During the soft launch period that started in November 2021, the game exhibited remarkable growth, accumulating over $30 million in bookings and more than 12 million downloads worldwide. It already placed 7th in the Farming games category by revenue and is now ranked 5th in terms of downloads. Island Hoppers is now entering a scaling phase, with increased marketing investments expected to fuel revenue and player base growth. As of September 2023, it is enjoyed by over 1 million players monthly.

08:07 EDT Jeffs' Brands expands Fort Brand to Amazon Marketplace in France - Jeffs' Brands (JFBR) announced the expansion of its brand of pest control solutions, Fort Brand, to the Amazon Marketplace (AMZN) in France. This strategic move marks another significant step in Jeffs' Brands' mission to provide top-notch pest control solutions to customers worldwide. Following the success of the Fort Brand in the United Kingdom, Jeffs' Brands recognizes the growing demand for its premium pest control products in the French market. French consumers, will now have access to Fort Band cutting-edge pest control solutions, offering effective and innovative products to address their needs. Viki Hakmon, Chief Executive Officer of Jeffs' Brands, expressed excitement about the expansion, stating, "The Fort Brand has consistently exceeded our expectations, and we are delighted to bring its renowned pest control solutions to the French consumers. We understand the importance of providing effective pest control products, and we are committed to meeting the needs of the French market."

08:04 EDT BIO-key selected by ALPI Portugal for secure data access - BIO-key International announced that ALPI Portugal Lda. has deployed AuthControl Sentry company-wide for enhanced data access security through BIO-key. The solution will utilize Multi-factor Authentication, MFA, access and Single Sign-on to secure data access by all of ALPI Portugal's internal users, including employees and third party drivers, as well as those with restricted access to their B2B website. The primary goal of this project was to implement MFA across all company systems for enhanced security during login. Additionally, ALPI aimed to enhance the user experience by integrating SSO with web platforms, to ensure protected B2B interactions. This integration allows and protects 24x7 tracking of deliveries from any location worldwide. BIO-key EMEA collaborated with ALTICE Portugal, a manager of cybersecurity projects, for this initiative.

07:59 EDT Medicenna Therapeutics CFO Jeff Caravella, CBO Brent Meadows depart - The Company announced the departure of Jeff Caravella as Chief Financial Officer, and Brent Meadows as Chief Business Officer, effective October 26th, 2023. The Company has started a search for a CFO familiar with the TSX.

07:58 EDT Medicenna Therapeutics to seek listing of common shares on OTC Markets - After careful consideration, the Board of Directors of Medicenna determined that it is in the overall best interests of the Company not to appeal Nasdaq's delisting decision and delist its common shares from Nasdaq. The Board's decision was based on several factors, including the continuing volatility of the financial markets in the life science sector and, accordingly, in the Company's current share price and market value, and an analysis of the benefits of continued listing on Nasdaq weighed against the regulatory burdens and costs associated with maintaining such listing. The Company anticipates significant financial savings as a result of this decision. With the common shares concurrently trading on the TSX, the Company believes that the significant costs associated with a continued Nasdaq listing, as well as the administrative burdens and extensive amount of management's time, attention and resources expended on regulatory compliance to maintain a Nasdaq listing, are not justified at this time. Following the delisting of the Company's common shares on the Nasdaq, the Company will also seek to have its common shares traded on the OTC Markets as soon as possible thereafter. Nasdaq has notified the Company that trading of its common shares will be suspended as of the opening of business on November 2, 2023, and a Form 25-NSE will be filed with the United States Securities and Exchange Commission, which will remove the Company's securities from listing and registration on Nasdaq.

07:49 EDT Masimo up 8% to $87 after ITC patent ruling on Apple Watches

07:37 EDT Cognition, Yale collaborators, ACTC announce presentation on START study - Cognition Therapeutics announced that Christoper van Dyck, M.D., the director of the Yale Alzheimer's Disease Research Unit and the Yale Alzheimer's Disease Research Center, is presenting the Phase 2 study design of the company's ongoing START study in an oral late-breaking session at Clinical Trials on Alzheimer's Disease conference. The START Study is assessing once-daily oral CT1812 or placebo in 540 individuals with early Alzheimer's disease for 18 months of treatment. Cognition Therapeutics is conducting the study in collaboration with the Alzheimer's Clinical Trials Consortium, ACTC, with major grant support from the National Institute of Aging at the National Institutes of Health. Published data points to a role for the sigma-2 receptor in regulating key "housekeeping" processes such as autophagy that are impaired in Alzheimer's and other neurodegenerative diseases. By binding to the -2 receptor on neurons, CT1812 may rescue these processes and protect neurons from further damage. We have collected the following clinical data, which we believe support the potential benefit that CT1812 may exert on synapse function and overall brain health: target engagement data demonstrated in the SNAP study; preliminary evidence of cognitive impact seen in the first cohort of patients in the SHINE study; reduced hippocampal atrophy observed via volumetric MRI in the SPARC study; and favorable impact on brainwave patterns as measured via quantitative electroencephalogram in the Phase 2 SEQUEL study.

07:36 EDT SHF Holdings restructures certain deferred consideration obligations - SHF Holdings, Inc., d/b/a/ Safe Harbor Financial announced the restructuring of certain deferred consideration payable to the shareholders of Rockview Digital Solutions, Inc, d/b/a Abaca, a cannabis-focused financial technology platform that was acquired by Safe Harbor in a transaction that closed on November 16, 2022. The combination of Safe Harbor's access to a wide range of financial service offerings and Abaca's industry-leading fintech software solutions has produced a comprehensive and streamlined banking solution for cannabis operators nationwide. The enhanced Safe Harbor fintech platform now offers desktop and mobile banking, treasury management, payment processing, cash handling, and logistics, as well as new interest-bearing and credit products announced earlier this year. The restructured terms provide for: a $2.00 conversion price on the $11.67 million in stock currently owed to Abaca shareholders, resulting in the issuance of 5,835,822 shares of SHF Holdings common stock, reducing anticipated dilution; the delivery of warrants to the Abaca shareholders to purchase up to 5 million shares of Company class A common stock at an exercise price of $2.00 per share; and a payment of $1.5 million in October 2025, which may be payable in stock, cash, or the combination of both, at the Company's option. The $3 million in cash consideration scheduled to be distributed to Abaca shareholders in both 2023 and 2024 remains unchanged.

07:34 EDT AppTech Payments completes acquisition of FinZeo - AppTech Payments announced that it completed its acquisition of Alliance Partners, owners of FinZeo, a software development company centered around the movement of money, nationally and globally. "This acquisition aligns seamlessly with AppTech's strategic initiatives, marking our steadfast commitment to investing in innovation and technology. We are resolute in our mission to foster revenue synergy and provide specialty payments for businesses and partners, while continuing to lead the way in the ever-evolving Fintech landscape," said Luke D'Angelo, Chairman & CEO of AppTech Payments Corp. "With FinZeo fully integrated into our Commerse(TM) product suite, we trust the market will be highly receptive to our comprehensive PaaS and BaaS solutions. We welcome the FinZeo team to our company and look forward to executing on our commercialization strategy to ultimately generate value for our shareholders."

07:33 EDT Saia sees 2023 net capex in excess of $400M - The company said, "In 2023, we anticipate that net capital expenditures will be in excess of $400 million, subject to ongoing evaluation of market conditions."

07:17 EDT 1933 Industries completes upgrades to Las Vegas cultivation facility - 1933 Industries provides a corporate update regarding the retrofit of its cultivation facility, upcoming tax relief events and the proposed amendments to its 10% Senior Unsecured Convertible Debentures Due December 31, 2023. The Company is pleased to announce that the upgrades and improvements undertaken over the last several months to its cultivation facility in Las Vegas have been completed. A large scale retrofit of the irrigation system was undertaken for the long-term success of the facility and the capital investment has already demonstrated significant improvements in flower production and yields. The Company also added an additional bloom room with 65 lights, thus increasing the total number of lights in the facility's 17 bloom rooms to 806. The Company anticipates that these enhancements will increase the Company's ability to offer consistent flower quality and value. The Company anticipates that its fourth quarter financial report will demonstrate revenue growth as a result of these improvements, with both the cultivation and production business units contributing to this strong performance. The Company's AMA brand continues to rank as one of the top selling brands in Nevada according to both BDSA and Headset cannabis market sales data. The Company will announce its fourth quarter financial report, as well as its year-end financial results on November 28, 2023. The Company will be holding an Extraordinary Meeting of the Holders of 10% Senior Unsecured Convertible Debentures due December 31, 2023, to seek approval for the following proposed amendments: To consider, and if thought fit, an extraordinary resolution, to: approve the settlement of the Debentures upon maturity and the principal debt owed thereunder, excluding any interest in arrears, through the issuance of a unit to the Debentureholders, each Unit being issued at a deemed price of $0.02 per Unit, comprising one common shares and one share purchase warrant exercisable into one additional common share of the Company at a price of $0.05 for a period of five years from the date of issuance, subject to certain acceleration provisions, with 50,000 Units being issued for each $1,000 in principal value Debentures held; or approve the settlement of the Debentures upon maturity and the principal debt owed thereunder, excluding any interest in arrears, through the issuance of a new 10% unsecured convertible debenture (the "New Debenture") with a two year maturity, convertible into units at a price of $0.05 per unit, each unit comprising one common share of the Company and one share purchase warrant exercisable into one additional common share of the Company at a price of $0.05 for a period of five years from the date of issuance of the New Debenture, subject to certain acceleration provisions as more particularly defined in the indenture governing warrants issuable upon conversion of the New Debenture. Options and above collectively referred to herein as the "Debenture Settlement Options" and authorize the Board of Directors of the Company, in its sole discretion, to determine which of or will be in the best interest of the Company and proceed with either or above. The Department of Health and Human Services recently recommended to the Drug Enforcement Administration that marijuana be rescheduled from a Schedule I to Schedule III substance, as defined by the Controlled Substances Act. If implemented, the rescheduling would have a significant impact on cannabis companies as it would eliminate 280E taxation. This tax prohibits cannabis operators from deducting business expenses from gross income, leading to higher taxes than ordinary businesses are required to pay. The recommendation is encouraging to companies operating in the sector and the Company will continue to follow any developments closely, with the expectation that tax relief will have a positive benefit on the industry. As of January 1st, 2024, the Company will gain relief as a change to the Nevada Wholesale Marijuana Tax comes into effect, amending how companies are taxed under the fair market value calculation. The WMT will apply to non-vertically integrated sales. Under existing law, the Department of Taxation determines the fair market value of wholesale cannabis and establishes a per pound rate, irrespective of the actual price of the product sold to dispensaries. The change means that a 15% tax will be calculated based on the actual sales price, resulting in significant cost savings for cultivators. The Company also announces the issuance of 1,000,000 stock options pursuant to the Company's stock option plan. The options are exercisable for a period of five years at a price of $0.05 per share.

07:13 EDT GameSquare's Complexity launches Cozy Clash - Complexity Gaming, a GameSquare company, announces Cozy Clash, a new tournament for the North American Game Changers scene, powered by Lenovo. GameSquare Holdings is proud to announce the new tournament as part of their continued efforts to create meaningful and impactful challenges for the gaming community. Cozy Clash will span over a month with top tier competition with the final stage to be played out in an IRL physical setting live from the Lenovo Legion Esports Center in Frisco, Texas. The finale will host four teams clashing over a $40,000 USD prize pool. The Cozy Clash will be an official part of the Riot Games OFF//SEASON program and the final VALORANT send-off for the record-setting year of 2023.

07:11 EDT Microbix Biosystems QAPs support HPV testing in Ireland - Microbix Biosystems announces that its quality assessment products are supporting a testing program for Human Papilloma Virus using molecular diagnostic technology at Dublin's The Coombe Hospital, in the Republic of Ireland, an EU member-state. Microbix's local distribution partner, The Medical Supply Company of Ireland has secured a tender-based contract to supply goods and services to support this national-level MDx and HPV-based cervical cancer screening program. The program is being driven by the instrumentation and reagents of the Roche Diagnostics Corporation cobas 6800/8800 Systems and cobas HPV test system, with Microbix REDx liquid-format IVD-regulated multiplex QAPs providing quality management system support to help ensure test accuracy. It is expected that the program will see regular participation by a majority of women of reproductive age within Ireland's overall population of 5.1 million.

07:08 EDT AC Immune announces data on ACI-12589 published in Nature Communications - AC Immune announced the publication of a peer-reviewed paper in Nature Communications showing the ability of an alpha-synuclein positron emission tomography tracer to identify patients with multiple system atrophy. The clinical trial of AC Immune's wholly owned experimental a-syn PET tracer ACI-12589 was led by the team of Oskar Hansson MD, PhD, at Lund University and Skundefinedne University Hospital, in collaboration with associates at InviCRO LLC, with the support of a grant from The Michael J. Fox Foundation for Parkinson's Research. The Nature Communications paper describes the first-in-human trial of ACI-12589 comparing healthy control subjects to patients with a-synucleinopathies and other neurological diagnoses. It concludes that ACI-12589 showed a specific and reproducible retention pattern in patients with MSA, indicating that the PET tracer could enable earlier, more accurate diagnosis of MSA and potentially, more precise monitoring of disease progression and responses to new a-syn targeted therapeutics in development.

07:06 EDT Prime Medicine presents prime editing data in primates for GSD1b - Prime Medicine reported new preclinical data demonstrating the ability of liver-targeted Prime Editors to efficiently and precisely correct one of the most prevalent disease-causing mutations of glycogen storage disease 1b in non-human primates - NHP - and mouse models. GSD1b is a rare, serious progressive disease that causes impaired glycogen metabolism and affects approximately 1,500 patients. To address the underlying genetic cause of GSD1b, Prime Medicine is advancing Prime Editors that are delivered to the liver by single intravenous infusion and designed to enable a precise correction of the disease-causing mutations. Prime researchers identified pegRNAs that precisely corrected the p.L348fs and p.G339C mutations in liver cells, which were then evaluated in vitro, demonstrating average editing of 77% and 37%, respectively.These findings provide important proof-of-concept for Prime Medicine's LNP liver-targeted delivery approach, and support the further advancement of the company's Prime Editors targeting the p.L348fs and p.G339C mutations in GSD1b.

07:05 EDT Alector achieves target enrollment in INFRONT-3 Phase 3 trial of latozinemab - Alector (ALEC) has achieved target enrollment in INFRONT-3, the pivotal Phase 3 clinical trial of latozinemab. INFRONT-3 is evaluating the safety and efficacy of latozinemab in slowing disease progression in individuals with frontotemporal dementia due to a progranulin gene mutation. Latozinemab is an investigational human monoclonal antibody designed to block sortilin, a degradation receptor for progranulin. It is intended to elevate PGRN levels and enhance the activity of microglia, the primary cells of the brain's innate immune system. Latozinemab is the most advanced PGRN modulating product candidate in clinical trials and the most advanced potential treatment for FTD-GRN. Latozinemab is being developed in collaboration with GSK (GSK). Earlier this year, Alector and GSK held a Type C meeting with the U.S. Food and Drug Administration and received scientific advice from the European Medicines Agency regarding INFRONT-3. The companies aligned with the FDA and EMA to conduct the primary analysis on symptomatic FTD-GRN participants, supporting an enrollment target of approximately 90-100 symptomatic participants in INFRONT-3. Alector and GSK achieved target enrollment in INFRONT-3 with 101 symptomatic participants.

07:04 EDT Charter: Q3 total residential, SMB internet customers up 63,000 - Third quarter total residential and small and medium business Internet customers increased by 63,000. As of September 30, 2023, Charter served a total of 30.6 million residential and SMB Internet customers. Third quarter total residential and SMB mobile lines increased by 594,000. As of September 30, 2023, Charter served a total of 7.2 million mobile lines. As of September 30, 2023, Charter had a total of 32.2 million residential and SMB customer relationships, which excludes mobile-only relationships.

06:58 EDT Colgate-Palmolive reports Q3 base gross profit margin up 140 bps to 58.6% - Base Business Gross profit margin increased 140 basis points to 58.6%, up 190 basis points excluding a negative 50 basis point impact from private label sales resulting from the previously disclosed acquisitions of pet food businesses.

06:46 EDT Exxon Mobil raises quarterly dividend to 95c from 91c per share - The corporation declared a fourth-quarter dividend of 95c per share, payable on Dec. 11, 2023, to shareholders of record of common stock at the close of business on Nov. 15, 2023. The company has increased its annual dividend for 41 consecutive years, including this increase of 4c per share, or 4%.

06:41 EDT ImmunoGen: EMA accepts MAA for mirvetuximab soravtansine - ImmunoGen announced that the European Medicines Agency has accepted the Marketing Authorization Application for mirvetuximab soravtansine for the treatment of patients with folate receptor alpha-positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer.

06:39 EDT LyondellBasell says confident will exceed annual EBITDA run rate target - "Implementation of LyondellBasell's long-term strategy remains our top priority. One year after launching our Value Enhancement Program, we are highly confident we will exceed our 2023 recurring annual EBITDA exit run-rate target of $200 million(c). The three pillars of our strategy reinforce each other. By stepping up our performance and culture with a pivot toward value creation, LyondellBasell will be able to grow and upgrade our core while building a profitable Circular and Low Carbon Solutions business. Looking ahead, we will continue to leverage our unique advantages to position LyondellBasell for a sustainable future," said Vanacker.

06:27 EDT Chart Industries divests American Fan business to Fairbanks Morse Defense - Chart Industries simultaneously signed and closed on the divestiture of its American Fan business to Fairbanks Morse Defense, a portfolio company of Arcline Investment, for an all-cash purchase price of $111M. The purchase price represents multiples in line with prior Chart transactions. American Fan designs, manufactures, and services high-performance axial and centrifugal fans for enduring U.S. Navy, Military Sealift Command, and U.S. Coast Guard platforms and specialty industrial applications. Cash proceeds have been used for debt paydown. The business operates in a dedicated facility in Fairfield, Ohio, which was included in the transaction. All employees of American Fan will be offered the opportunity to continue employment with FMD.

06:24 EDT Sanofi says capital allocation policy remains unchanged - Sanofi said: "The company's capital allocation policy remains unchanged. Sanofi expects to maintain a gradually growing dividend, consistent with its historical dividend policy. Third quarter 2023 results and the announcements above will be discussed by management during a conference call with the financial community today... Sanofi will host an R&D Day for investors and analysts in New York City on December 7, 2023."

06:19 EDT Chevron CEO says 'delivered another quarter of solid financial results' - "We delivered another quarter of solid financial results and strong cash returns to shareholders," said Mike Wirth, Chevron's chairman and CEO. "Earnings have exceeded $5 billion, and ROCE has been greater than 12 percent for nine consecutive quarters. Cash returned to shareholders totaled $20 billion year-to-date, 27 percent higher than last year's record total for the same period. The acquisition of PDC Energy strengthened our position in important U.S. production basins," Wirth continued. "The DJ Basin now ranks among Chevron's top-five producing assets. "We also acquired a majority stake in ACES Delta, LLC, the United States' largest green hydrogen production and storage hub," Wirth commented. "Chevron is delivering strong financial results while also investing to profitably grow our traditional and new energy businesses to drive superior value for shareholders," Wirth concluded.

06:13 EDT GM's Cruise pauses driverless operations after California ban - In a set of Thursday tweets, Cruise said, "The most important thing for us right now is to take steps to rebuild public trust. Part of this involves taking a hard look inwards and at how we do work at Cruise, even if it means doing things that are uncomfortable or difficult...In that spirit, we have decided to proactively pause driverless operations across all of our fleets while we take time to examine our processes, systems, and tools and reflect on how we can better operate in a way that will earn public trust...This isn't related to any new on-road incidents, and supervised AV operations will continue. We think it's the right thing to do during a period when we need to be extra vigilant when it comes to risk, relentlessly focused on safety, & taking steps to rebuild public trust." Reference Link

06:09 EDT Trivago announces ratio change under American Depositary Share program - Trivago announced that its management board has approved a change of ratio in the company's American Depositary Share program, comprising a change in the ratio of American Depositary Shares to trivago class A shares from one ADS representing one Share, to one ADS representing five Shares. The effective date of the Ratio Change is expected to be November 7, 2023. Pursuant to the Ratio Change, as of the Effective Date, record holders who directly hold ADSs will be required to exchange their existing ADSs for new ADRs on the basis of one new ADR for every five existing ADSs surrendered. The Depositary will contact the Company's ADS holders and arrange for the exchange of their existing ADSs for new ADSs. ADS beneficial holders who hold through an ADS holder intermediary need not take any action in connection with the Ratio Change. No new Shares will be issued in connection with the Ratio Change. The ADSs will continue to be traded on The Nasdaq Stock Exchange under the symbol "TRVG." Additionally, as previously announced, the company's management board, with the approval of its supervisory board, has resolved to issue a one-time extraordinary dividend, totaling EUR 184,380,959. As previously announced, part of this extraordinary dividend in the amount of EUR 167,893,889 is subject to trivago shareholder approval. The dividend is expected to equal EUR 0.529228 per Share for those holders as of record on November 3, 2023. The payment of the distribution on the ADS is anticipated to be made on November 13, 2023.

05:34 EDT Opthea CEO Megan Baldwin to transition out of role, Frederic Guerard to succeed - Opthea announced that the company's CEO, Megan Baldwin, will transition to founder and chief innovation officer, effective immediately, reflective of the company's strategy to advance its U.S. and global presence and commercialization strategy for sozinibercept. Concurrently, Opthea is pleased to announce the appointments of U.S.-based executives, Frederic Guerard as CEO and Peter Lang as CFO. Guerard served as the CEO of Graybug Vision, a clinical-stage pharmaceutical company developing potentially transformative therapies for ocular diseases.

05:24 EDT Calliditas announces Everest Medicines receives approval for Nefecon - Calliditas Therapeutics announced that its commercial partner Everest Medicines received approval from the Pharmaceutical Administration Bureau of the Macau Special Administrative Region, China. The approval for Nefecon is for the treatment of primary immunoglobulin A nephropathy, or IgAN, in adults at risk of disease progression. Macau is the first region in Everest territories that received Nefecon approval. The NDA for Nefecon in mainland China is under Priority Review and Nefecon was the first non-oncology medicine to receive Breakthrough Therapy Designation in China. Nefecon has been available for clinical use in Shanghai Ruijin Hospital's Hainan subsidiary through an early-access program since April.

05:15 EDT Embraer to sell 19 E175 jets to SkyWest - Embraer (ERJ) has agreed to the sale of 19 new E175 jets to SkyWest, Inc. (SKYW) for operation in the United Airlines (UAL) network, adding to the 90 E175 jets SkyWest already operates for United. The E175 aircraft will fly exclusively with United under a Capacity Purchase Agreement, or CPA. The value of the contract, which has been included in Embraer's Q3 backlog, is $1.1B, based on list price. The 70-seat aircraft will be delivered in a three-class configuration. Deliveries will begin Q4 2024.